

PRESS RELEASE

Physidia expands in Europe with the opening of its German subsidiary

FOR IMMEDIATE RELEASE

Angers, France – November 4th, 2025 - Physidia, a French MedTech company specialized in innovative home hemodialysis solutions, is proud to announce the creation of its German subsidiary, Physidia GmbH.

This strategic expansion marks a significant step in strengthening Physidia's leading presence in Europe and advancing its long-term commitment to making frequent home dialysis more accessible for patients.

This local presence will enable the company to better support German healthcare providers in implementing frequent home hemodialysis — a therapy proven to enhance patient clinical outcomes and daily lives^{1,2}.

About 80.000 patients are currently treated on dialysis in Germany, and less than 1% are performing home hemodialysis. This reveals a significant gap in access to home-based therapies compared with other European countries, highlighting the need to expand and optimize home dialysis programs.



Julien Dolivet, CEO of Physidia, alongside the S³ home hemodialysis monitor developed to enhance patients' health, quality of life, and freedom.

"With the launch of Physidia GmbH, we are reinforcing our commitment to collaborate closely with German healthcare professionals and promote home-based dialysis therapies that improve patients' health, quality of life, and freedom," said Julien Dolivet, CEO of Physidia.

Through its innovative solution, designed for home use — combining the S³ home hemodialysis monitor, PhysiNums® remote data platform, and dedicated training services — Physidia provides healthcare professionals and patients with an effective and reliable therapy.

Home hemodialysis improves patients' health, quality of life, and freedom

Home hemodialysis, an alternative to in-center treatment, enables patients to receive frequent dialysis sessions in the comfort and safety of their own homes. This approach is the most physiological and significantly improves patients' quality of life by reducing fatigue, allowing for rapid recovery, and offering more free time. Clinical benefits include improved hemodynamic and nutritional stability, reduced cardiovascular complications, and a significant decrease in mortality rates^{1,2}.

Although the treatment may initially appear more expensive than in-center care, this is not the case when considering the total cost to the community, this changes when the broader economic context is considered. Transportation alone accounts for a cumulative 14% reduction in costs. In addition, enabling patients to return to work—or to maintain employment—creates a substantial socioeconomic benefit, as individuals previously on long-term sick leave become valuable contributors to the economy once again.³

Finally, home hemodialysis provides a practical and sustainable response to the current shortage of hospital staff.

Bibliographic references:

1. *Safety and Efficacy of Short Daily Hemodialysis with Physidia S³ System: Clinical Performance Assessment during the Training Period*, H. Fessi et al, J. Clin. Med. 2022, 11, 2123

2. *Two Years' Experience of Intensive Home Hemodialysis with the Physidia S³ System: Results from the RECAP Study*, H. Fessi et al, *J. Clin. Med.* 2023, 12, 1357

3. *Cost-effectiveness of daily home hemodialysis versus in-center hemodialysis: A propensity score matching analysis based on real-world data from the French healthcare system*. Rostoker, Guy et al. *European journal of internal medicine* vol. 137 (2025)

Bibliography: <https://www.physidia.com/en/bibliographic-references/>

About Physidia

Founded in Angers in 2011, Physidia has become a European leader in home hemodialysis by developing a portable monitor, the S³®. After obtaining CE marking in 2013, the company expanded its presence to 18 markets, mainly in Europe and the Middle East.

The innovative technology of the S³® monitor is specifically designed to provide high-quality, safe, and comfortable dialysis for patients at home. Today over 1,400 patients undergo dialysis daily with the S³® and more than 1.3 million sessions have been completed.

The company's rapid growth and international expansion demonstrate its ability to innovate and respond to the challenges of the healthcare market. Physidia has been named "Growth Champion" by Les Echos on several occasions, as well as "Europe's Long-Term Growth Champion" by the Financial Times.

Physidia Vision and Mission

Our vision: Make People's lives better. We rethink dialysis to adapt it to patients, not the other way around.

Our mission: Improve health, Quality of Life, and Freedom for those who are using our innovative solutions. Each technological advancement we develop aims to provide patients with greater autonomy and peace of mind.

Press Contact

Claire Daculsi
Global Product Marketing Manager – Physidia
Email: claire.daculsi@physidia.fr
Website: www.physidia.com

© Physidia 2025 – All rights reserved

For more information about Physidia's home hemodialysis solutions, visit www.physidia.com.